Active, not recruitingPHASE1, PHASE2NCT04983030

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Boris Juelg, MD PhD
Principal Investigator
Boris D Juelg, MD PHD
Beth Israel Deaconess Medical Center
Intervention
Ad26.Mos4.HIV(biological)
Enrollment
36 enrolled
Eligibility
18-70 years · All sexes
Timeline
20222026

Study locations (6)

Collaborators

Janssen Pharmaceuticals · Harvard School of Public Health (HSPH) · National Institute of Allergy and Infectious Diseases (NIAID)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04983030 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency

← Back to all trials